Compatibility of Estradiol, Estriol, Estrone, Progesterone, and Testosterone Single Formulation in Fitalite, Versatile, or HRT Supreme Cream Base

Polonini, Hudson C; Dijkers, Eli; Ferreira, Anderson O; Zander, Clark; Taylor, Sarah

Abstract

Compatibility of Estradiol, Estriol, Estrone, Progesterone, and Testosterone Single Formulation in Fitalite, Versatile, or HRT Supreme Cream Base

Author(s): Polonini Hudson C, Dijkers Eli, Ferreira Anderson O, Zander Clark, Taylor Sarah

Issue: Jul/Aug 2021 - Volume 25, Number 4

View All Articles in Issue

Page(s): 336-343

Download in electronic PDF format for $75

Abstract

In this work, we focus on three ready-to-use vehicles: Fitalite, Versatile, and HRT Supreme Cream Base. Fitalite is a natural, light, hydrophilic gel-cream that contains vitamin E and oil bodies from plant sources (phytosomes), providing antioxidant and skinmoisturizing properties. Versatile is a vanishing oil-inwater cream base which retains its consistency with a broad range and high concentrations of active pharmaceutical ingredients, dermaceutical ingredients, and solvents. Finally, HRT Supreme Cream Base is a paraben-free, dye-free, fragrance-free O/W emulsion base, formulated with a complex of botanical oils to soothe and provide moisture to dry and sensitive skin. In the current study, we evaluated the beyond-use date of formulations containing estradiol, estriol, estrone, progesterone, and testosterone in combination, compounded with these three vehicles. Validated, stability-indicating high-performance liquid chromatography methods were used throughout a 180-day period. A beyond-use date of 180 days was observed for all vehicles stored both at refrigerated and at room temperature. The combination of five ingredients represents a worst-case scenario since there are more possibilities of cross reactions. Therefore, we expect the same or greater stability as individual ingredients are removed from the tested formulation. The extended beyond-use dates provide convenience for both the compounding pharmacist and the patient.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Jul/Aug 2021 Pg. 336-343	Compatibility of Estradiol, Estriol, Estrone, Progesterone, and Testosterone Single Formulation in Fitalite, Versatile, or HRT Supreme Cream Base Author(s): Polonini Hudson C, Dijkers Eli, Ferreira Anderson O, Zander Clark, Taylor Sarah
May/Jun 2017 Pg. 238	Tri-Est, Progesterone, and Testosterone in Versatile, Phytobase, Fitaline, and HRT Supreme Cream Bases Author(s): Allen Loyd V Jr
Sep/Oct 2016 Pg. 407	Estradiol 0.25 mg/g, Estrone 0.25 mg/g, and Estriol 2 mg/g in HRT Cream Base Author(s): Allen Loyd V Jr
Jan/Feb 2001 Pg. 52-54	Using Serum Hormone Analysis to Develop Hormone Replacement Therapy Regimens - Part 2 Author(s): Ford Gina, Garcia Lea
Jul/Aug 2002 Pg. 298	Estriol 2-mg/mL, Estrone 0.25-mg/mL, and Estradiol 0.25-mg/mL Topical Solution Author(s): Allen Loyd V Jr
Mar/Apr 2002 Pg. 142-146	Bioidentical Hormone Replacement Therapy, Part 3, A Review of Author(s): Wepfer Scott T
Nov/Dec 2000 Pg. 458	Estriol and Estradiol 2.5-mg, Progesterone 50-mg, and Testosterone 1-mg Capsules Author(s): Allen Loyd V Jr
Sep/Oct 2009 Pg. 392-399	Saliva Tests, Part 2: Salivary Hormones, Hormone Replacement Pharmacokinetics, and the Importance of Timely Testing Author(s): Kells John, Dollbaum Charles M
Jan/Feb 2015 Pg. 6-12	Efficacy and Clinical Value of Commonly Compounded Hormone Replacement Therapy: A Literature Review Author(s): Beshay Sarah M, Rivera Gerard, Balthasar Jan, Florea Naomi
Mar/Apr 2021 Pg. 156-162	Stability of Fagron's Phytobase Cream Compounded with Various Hormones Author(s): Wynn Tom, Taylor Sarah, Zander Clark
Mar/Apr 2012 Pg. 110-114	Bilateral Areolar Hyperpigmentation Following Transdermal Administration of Compounded Hormone Replacement Therapy Author(s): Griffee Chris, Delano Amy
Jul/Aug 2003 Pg. 250-256	A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 1 Author(s): Gillson George R, Zava David T
Jan/Feb 2024 Pg. 22-27	Establishing a Rationale for Compounding Hormone Replacement Therapy Author(s): Biundo Bruce
May/Jun 2018 Pg. 190-195	Establishing a Rationale for Compounding Hormone Replacement Therapy Author(s): Biundo Bruce
Jan/Feb 2017 Pg. 39-45	Basics of Compounding with Dilutions and Concentrates Author(s): Allen Loyd V Jr
Jan/Feb 2002 Pg. 50-54	Bioidentical Hormone Replacement Therapy, Part 2, A Review of Author(s): Wepfer Scott T
Jan/Feb 1998 Pg. 54	Progesterone-Estradiol-Testosterone in Oil Capsules Author(s): Allen Loyd V Jr
Sep/Oct 2016 Pg. 412	Progesterone 10% Cream Author(s): Allen Loyd V Jr
Nov/Dec 2018 Pg. 466-468	Case Study: Absorption of Testosterone Cream via Scrotal Delivery Author(s): Needham Shawn, Needham Shane
Jul/Aug 2009 Pg. 314-317	Poster Presentation Report: Safety of Maternal Testosterone Therapy During Breast Feeding Author(s): Glaser Rebecca L, Newman Mark, Parsons Melanie, Zava David, Glaser-Garbrick Daniel